

Serial No. 08/533,895

Docket No. 2026-4205

97. (new) A-derivative of the peptide according to claim 94, wherein the L at position 5 is changed to a F (phenylalanine). *56 74*

98. (new) A derivative of the peptide according to claim 94, wherein the A at position 8 is changed to a V (valine). *92 5*

99. (new) A derivative of the peptide according to claim 94, wherein the L at position 10 is changed to a V (valine). *52 3*

REMARKS

Applicants gratefully acknowledge the telephone call with Examiner Turner and Examiner Kunz. The telephone call imposed a restriction requirement and requested oral election of one of the two groups of claims identified during the telephone call. The first group encompasses claims directed to peptides from the region containing amino acids 56-70 (Group I) and the second group encompasses claims directed to peptides from the region containing amino acids 448-462 (Group II). Group I includes peptides having the Sequence ID Nos: 1-5, 18-19 and 24. These peptides are directed to a single peptide, SEQ ID NO:1, and single point mutants thereof. Group II includes peptides having the Sequence ID Nos: 6-14 and 37-38. These peptides are directed to a single peptide, SEQ ID NO:6, and mutants thereof.

Applicants hereby elect Group I. The claims have been amended and new claim added so as to be directed to subject matter related to Group I peptides. No new matter has been added, nor do the amended claims add any new issues of patentability.

Applicants respectfully request favorable consideration of the present application and claim. Early and favorable action by the Examiner is earnestly solicited.

No additional fee is believed to be necessary.

Serial No. 08/533,895

Docket No. 2026-4205

The Commissioner is hereby authorized to charge any additional fees which may be required for this amendment, or credit any overpayment to Deposit Account No. 13-4500, Order No. 2026-4205.

In the event that an extension of time is required, or which may be required in addition to that requested in a petition and for an extension of time, the Commissioner is requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. 13-4500, Order No. 2026-4205.

A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

By: Dorothy R. Auth

Dorothy R. Auth
Registration No. 36,434

Dated: April 2, 2002

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849 Telecopier

Serial No. 08/533,895

Docket No. 2026-4205

MARKED UP VERSION OF THE AMENDED CLAIMS

64. (amended) An isolated Major Histocompatibility Complex Class II

immunogenic peptide, wherein said peptide comprises a ¹³ 9 amino acid segment of a sequence selected from the group consisting of QNILLSNAPLGPQFP (Ty 56-70) (SEQ ID NO: 1), and NILLSNAPLGPQFP (Ty 57-70) (SEQ ID NO: 2)[, DYSYLQDSDPDSFQD (Ty 448-462) (SEQ ID NO: 6), YSYLQDSDPDSFQD (Ty 449-462) (SEQ ID NO: 13), and SYLQDSDPDSFQD (Ty 450-462) (SEQ ID NO: 14)].

65. (amended) The isolated Major Histocompatibility Complex Class II

immunogenic peptide, wherein said peptide is selected from the group consisting of QNILLSNAPLGPQFP (Ty 56-70) (SEQ ID NO: 1), and NILLSNAPLGPQFP (Ty 57-70) (SEQ ID NO: 2)[, DYSYLQDSDPDSFQD (Ty 448-462) (SEQ ID NO: 6), YSYLQDSDPDSFQD (Ty 449-462) (SEQ ID NO: 13), SYLQDSDPDSFQD (Ty 450-462) (SEQ ID NO: 14), YLQDSDPDSFQD (Ty 451-462) (SEQ ID NO: 37) and LQDSDPDSFQD (Ty 452-462) (SEQ ID NO: 38)].

66. (amended) An isolated Major Histocompatibility Complex Class II

immunogenic peptide, wherein said peptide comprises a 9 amino acid segment of a sequence selected from the group consisting of QNILLSNAPVGPQFP (Ty 56-70, L65→V) (SEQ ID NO: 3), QNILLSNVPVGPQFP (Ty 56-70, A63→V and L65→V) (SEQ ID NO: 4), and QNILLSNVPLGPQFP (Ty 56-70, A63→V) (SEQ ID NO: 5)[, DYSYLQDSDPDSFQD (Ty 448-462, F460→S) (SEQ ID NO: 7), DQSYLQDSDPDSFQD (Ty 448-462, Y449→Q) (SEQ ID NO: 8), DFSYLQDSDPDSFQD (Ty 448-462, Y449→F) (SEQ ID NO: 9), DYSFLQDSDPDSFQD (Ty 448-462, Y451→F) (SEQ ID NO: 10), DYSYLQDSVPDSFQD

Serial No. 08/533,895

Docket No. 2026-4205

(Ty 448-462, D456→V) (SEQ ID NO: 11) and SYLQDSVPDSFQD (Ty 450-462, D456→V) (SEQ ID NO: 12)].

67. (amended) An isolated Major Histocompatibility Complex Class II immunogenic peptide, wherein said peptide is selected from the group consisting of QNILLSNAPVGPQFP (Ty 56-70, L65→V) (SEQ ID NO: 3), QNILLSNVPVGPQFP (Ty 56-70, A63→V and L65→V) (SEQ ID NO: 4), QNILLSNVPLGPQFP (Ty 56-70, A63→V) (SEQ ID NO: 5), [DYSYLQDSDPDSSQD (Ty 448-462, F460→S) (SEQ ID NO: 7), DQSYLQDSDPDQD (Ty 448-462, Y449-Q) (SEQ ID NO: 8), DFSYLQDSDPDQD (Ty 448-462, Y449→F) (SEQ ID NO: 9), DYSFLQDSDPDQD (Ty 448-462, Y451→F) (SEQ ID NO: 10), DYSYLQDSVPDSQD (Ty 448-462, D456→V) (SEQ ID NO: 11) SYLQDSVPDSQD (Ty 450-462, D456→V) (SEQ ID NO: 12),] QNFLLSNAPLGPQFP (Ty 56-70, I58→F) (SEQ ID NO: 18), QNVLLSNAPLGPQFP (Ty 56-70, I58→V) (SEQ ID NO: 19), and QNLFSNAPLGPQFP (Ty 56-70, L60→F) (SEQ ID NO: 24).